Cytokinetics Inc’s recently made public that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $0.14 million on Nov 04 ’25. In the deal valued at $59.55 per share,2,295 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 140,610 shares worth roughly $8.38 million.
Then, Blum Robert I sold 5,000 shares, generating $314,300 in total proceeds. Upon selling the shares at $62.86, the President & CEO now owns 358,108 shares.
Before that, WIERENGA WENDELL sold 4,375 shares. Cytokinetics Inc shares valued at $256,725 were divested by the Director at a price of $58.68 per share. As a result of the transaction, WIERENGA WENDELL now holds 32,444 shares, worth roughly $1.93 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -0.68% to $59.62. Over the last five days, the stock has lost -3.79%. Cytokinetics Inc shares have risen nearly 16.90% since the year began. Nevertheless, the stocks have risen 26.74% over the past one year. While a 52-week high of $64.13 was reached on 10/30/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 58.79, which if violated will result in even more drops to 57.96. On the upside, there is a resistance level at 60.61. A further resistance level may holdings at 61.60.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-10-15, dropping by 58965.0 shares to a total of 14.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 14.26 million shares. There was a decline of -0.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
